Despite the established role of insulin-like growth factor binding protein-3 (IGFBP-3) as a growth inhibitor in vitro, a high level of IGFBP-3 in breast tumor tissue is associated with the stimulation of xenograft growth in mice and poor prognosis in patients. To understand the contribution of IGFBP-3 to breast cancer progression, tandem affinity purification was used to identify novel interacting proteins. The endoplasmic reticulum protein, glucose-regulated protein 78 (GRP78), was shown to bind to IGFBP-3, confirmed by colocalization, coimmunoprecipitations, glutathione S-transferase (GST) pulldowns and a nanomolar binding affinity. GST pulldowns also indicated that the GRP78 ATPase domain mediated the interaction with IGFBP-3. The critical roles of GRP78 in the unfolded protein response and macroautophagy led to an investigation of possible links between IGFBP-3, GRP78 and cellular stress responses. IGFBP-3 was found to stimulate the survival of breast cancer cells subjected to glucose starvation and hypoxia. Pharmacological inhibitors and small interfering RNA knockdown established that the increased survival of IGFBP-3-expressing cells was dependent on an intact autophagy response, as well as GRP78. The contribution of autophagy was confirmed by the demonstration that IGFBP-3 expression increases both the formation of autophagic puncta and flux through the system. In conclusion, we have shown that IGFBP-3 stimulates autophagy and thereby promotes the survival of breast cancer cells exposed to conditions that represent the adverse microenvironments encountered by solid tumor cells in vivo.
INTRODUCTION
Insulin-like growth factor binding protein-3 (IGFBP-3) is one of a family of six IGFBPs that control the bioavailability of IGF-I and IGF-II, and hence the potent proliferative and anti-apoptotic signals instigated by these two closely related growth factors. 1 Because IGFBP-3 has been associated with cancer, in particular breast tumorigenesis, the ability of serum IGFBP-3 to influence tumor growth by controlling IGF bioavailability has received intense scrutiny. However, the substantial number of serum studies performed have done little to clarify the impact of IGFBP-3 on cancer, 2 suggesting that IGFBP-3 might predominantly influence tumor growth at the local level. Indeed, a number of clinical investigations have indicated that IGFBP-3 directly produced by breast tumor cells may promote cancer. [3] [4] [5] [6] The IGFBP-3 actions at the local tumor level are likely to be complex, because of an array of interactions with IGFs and other extracellular ligands. [7] [8] [9] [10] Furthermore, although a predominantly secreted protein, IGFBP-3 has also been reported to interact with a number of nuclear partners. [11] [12] [13] Thus, IGFBP-3 has been proposed to exert both extracellular and intracellular influences on processes such as cell migration, adhesion, apoptosis and proliferation via IGFindependent mechanisms. 1, 14, 15 The importance of intracellular mechanisms to breast cancer is supported by data from our cellculture models, where IGFBP-3 expression, 16 but not the addition of exogenous recombinant protein, 17 inhibited the growth of T47D cells. Taken together, it would appear that intracellular IGFindependent functions provide critical mechanisms, whereby IGFBP-3 influences breast cancer cell growth.
Given the complexity of IGFBP-3 interactions, we sought to gain functional insights by using tandem affinity purification (TAP) to purify intracellular binding partners. The TAP identified glucoseregulated protein 78 (GRP78), a protein with a number of intracellular functions that are central to the response of solid tumor cells to adverse microenvironments, including an essential requirement for the initiation of macroautophagy 18 (hereafter called autophagy). We demonstrate that IGFBP-3 promotes autophagy and thereby enhances the survival of breast cancer cells challenged by nutrient starvation and hypoxia.
RESULTS

Identification of GRP78 by TAP
A TAP approach was chosen as a relatively unbiased way to identify endogenous intracellular IGFBP-3-binding partners. IGFBP-3 was engineered with 6 Â His-1 Â FLAG tags fused to the C-terminus of the protein (Figure 1a ). Pooled stable clones of T47D breast cancer cells were generated for untagged and TAPtagged IGFBP-3 derivatives, as well as an empty-vector control. The IGFBP-3-expressing clones produced a similar low level of protein (data not shown). Proliferation assays indicated that the 6 Â His-1 Â FLAG construct inhibited growth to the same extent as untagged IGFBP-3, whereas derivatives tagged with larger epitopes were deemed unsuitable, as they only marginally inhibited growth (data not shown).
Large scale TAPs from T47D low-passage 6 Â His-1 Â FLAG tagged IGFBP-3 or empty-vector control cells were performed. As IGFBP-3 is a secreted protein that also binds nuclear partners, we chose to use a crude nuclear extract that included the major secretory pathway organelles, as verified by marker proteins for each compartment (Supplementary Figure 1) . Analysis of proteins eluted from the second round of affinity purification revealed a unique 78-kDa band (Figure 1b ). An identical banding pattern was observed from TAP with an IGFBP-3 mutant, lacking a functional nuclear localization signal (data not shown). Peptide mass fingerprinting unambiguously identified the 78-kDa protein as GRP78/HSPA5/BiP, based on 13 peptides with a sequence coverage of 44.5%. GRP78 is a member of the Hsp70 family of chaperones that resides in the endoplasmic reticulum (ER) and has established roles in promoting cancer initiation, further progression of tumors and the development of therapeutic resistance, particularly in breast cancer. [19] [20] [21] The interaction of IGFBP-3 and GRP78 was confirmed by coimmunoprecipitation of ectopic proteins (Figure 1c) , as well as coimmunoprecipitation of endogenous proteins from MDA-MB-468 breast cancer cells (Figure 1d) (Figure 1a) . Thus, two differentially glycosylated forms of IGFBP-3 are routinely detected by western blotting (Figures 1b-d) .
IGFBP-3 exhibits high-affinity binding to the GRP78 ATPase domain As the C-terminal GRP78 domain (Figure 2a ) binds folding intermediates in the ER lumen, it could associate with newly synthesized IGFBPs, thereby calling into question the functional importance of the IGFBP-3-GRP78 association. To address this issue, we used several approaches. First, full-length GRP78 fused to GST was utilized for in vitro pulldowns with recombinant protein for each of the six IGFBPs. IGF ligand blots indicated that only IGFBP-3 and IGFBP-5 were pulled down by GRP78-GST (Figure 2b ). In keeping with the known 'stickiness' of these two IGFBPs, a low level of background binding to GST was also observed ( Figure 2b) .
Next, the N-terminal ATPase domain of GRP78, but not its C-terminal substrate-binding domain, was shown to mediate the interaction ( Figure 2c ). As structural studies have indicated that the GRP78 ATPase domain folds into four discrete lobes, 23 we generated lobe-specific GST fusions (Figure 2a ). GRP78 lobe IIB, consisting of amino-acid residues 236-314, was found to represent the minimal binding region (Figure 2d ). The demonstration that IGFBP-3 has an association constant of 1.26 ± 0.87 l/nmol for GST-GRP78 (Figure 2e ) provided further evidence that the interaction is likely to be functionally and biologically significant. IGFBP-3 enhances stress survival Known cancer-related functions of GRP78 include (1) its role as the master regulator of the unfolded protein response (UPR), 24 (2) an essential requirement in autophagy, 18 (3) the direct inhibition of proapoptotic signaling molecules 25, 26 and (4) activities associated with the small proportion of GRP78 that localizes to the plasma membrane. 27 We used breast cancer cell culture models to test whether IGFBP-3 influences functions 1-3, as they reflect intracellular activities of GRP78 that are consistent with the nuclear/secretory organelle fraction used for TAP. To circumvent adaptive responses that may arise from long-term expression of IGFBP-3 in breast cancer cells, 16 we generated doxycycline (dox)-inducible clones derived from the breast cancer cell line MCF7 Tet-On Advanced. Individual low-(clone 6) and highexpressing (clone 23) IGFBP-3-inducible cell lines with negligible levels of basal expression were chosen (Figure 3a) .
A high degree of colocalization between IGFBP-3 and endogenous GRP78 (a classical ER marker) was observed in dox-treated cells (Figure 3b ). Similar results were obtained for endogenous IGFBP-3 and GRP78 in the Hs578T breast cancer cell line (Supplementary Figure 2) . Additional authentication of the interaction was provided by coimmunoprecipitation of endogenous GRP78 with IGFBP-3 from dox-induced clone 23 cells, but not from uninduced cells (Supplementary Figure 3) .
Proliferation assays confirmed that IGFBP-3 expression significantly (Po0.0001) inhibited in vitro growth under standard culture conditions (Supplementary Figure 4) , as we 17 and others 28 have previously reported. Addition of dox at the concentration used throughout this study (0.25 mg/ml) had no effect on the proliferation of the parental cell line (data not shown), indicating that the observed effects are due to IGFBP-3 expression. The influence of IGFBP-3 on cell growth under in vitro conditions that more closely mimic tumor microenvironments was then assessed. This approach was prompted by two observations: (1) GRP78 is critical to the UPR and autophagy, two cellular stress responses that are central to surviving adverse in vivo microenvironments and (2) environmental differences may explain the discrepancy between IGFBP-3 inhibition of in vitro breast cancer cell proliferation (confirmed in this study) and the ability of IGFBP-3 to promote xenograft growth. 29 Upon exposure to hypoxia (1% O 2 ) combined with glucose starvation, a significant (435%; Po0.05) increase in survival was observed for IGFBP-3 ( þ dox) cells over a 16-24-h period (Figure 3c ). Although IGFBP-3 inhibits growth in the absence of stress in the long term (Supplementary Figure 4) , no discernable effect was seen for periods o48 h (data not shown). IGFBP-3-expressing cells also exhibited enhanced growth and survival when treated with two pharmacological inducers of ER stress, tunicamycin (tuni) and 2-deoxyglucose (2-DG) (Figure 3d) . The above results were confirmed by subjecting the second dox-inducible cell line to the same range of treatments (Supplementary Figure 5) .
Long-term clonogenic survival assays further demonstrated that IGFBP-3 confers an advantage when cells are subjected to hypoxia and glucose starvation (Figure 3e ), with the dox-induced cells exhibiting an 83% increase in survival after 16 h of starvation, compared with uninduced cells. In keeping with the previous reports that IGFBP-3 is growth inhibitory under the standard culture conditions, IGFBP-3 expression caused a 25% decrease in colony formation in non-starved cells.
Key aspects of the UPR are not altered by IGFBP-3 As hypoxia, glucose starvation, tuni and 2-DG induce ER stress and GRP78 is the master regulator of the UPR, 24 the potential influence of IGFBP-3 on the UPR was investigated. Induction of IGFBP-3 expression had no influence on key UPR signaling events after a 24-h exposure to tuni, including splicing of XBP1 mRNA and proteolytic cleavage of ectopic or endogenous ATF6 protein ( Supplementary Figures 6a-c) . Likewise, no changes were observed in the third major arm of UPR signaling, as assessed by the phosphorylation status of PERK (Supplementary Figure 6d) . IGFBP-3 also failed to elicit transcriptional changes in the genes for the major UPR targets, GRP78, GRP94 and CHOP, either in the absence or presence of ER stress (Supplementary Figure 6e) . Because similar results were obtained when the above analyses were performed at earlier time points (4-6 h) or after a transient exposure to tuni (data not shown), we conclude that IGFBP-3 binding to GRP78 does not significantly alter UPR signaling. As positive controls, tuni stimulated production of cleaved endogenous ATF6, phosphorylation of PERK and activation of UPR-target gene expression (Supplementary Figures 6c-e) , whereas splicing of XBP-1 mRNA was not detectable in the absence of tuni (data not shown).
IGFBP-3 stimulation of stress survival is dependent on autophagy and GRP78 Tunicamycin and 2-DG have recently been found to activate autophagy, 30, 31 as does microenvironmental stress caused by hypoxia and glucose starvation. 32 As GRP78 is also involved in autophagy, 18 we probed possible links between IGFBP-3, GRP78 and autophagy. The classic pharmacological inhibitor of autophagy under starvation conditions, the phosphoinositide 3-kinase inhibitor 3-methyladenine (3-MA), 33 clearly negated the survival advantage conferred by IGFBP-3 ( Figure 4a ). Treatment with wortmannin, another phosphoinositide 3-kinase and autophagy inhibitor, also abrogated the IGFBP-3 effect (Figure 4a ). It should be noted that 3-MA has been reported to also block the UPR, whereas wortmannin is not considered to do so. 18 Thus, the lack of any significant IGFBP-3 effect in the presence of wortmannin (Figure 4a ) indicates that the IGFBP-3-survival advantage is dependent on autophagy, not the UPR. This is entirely in keeping with our inability to detect IGFBP-3 influences on UPR signaling. The reduced viability of 3-MA-treated cells (Figure 4a ) is consistent with the ability of this drug to block the two survival pathways. 125 I-IGFBP-3 bound to GST-GRP78 in the presence of unlabeled IGFBP-3 to that bound in the absence of unlabeled IGFBP-3. Data shown is representative of two independent assays set up with duplicate samples. Data from these assays were analyzed by Scatchard plot (right-hand graph shows a representative plot); K a ¼ 1.26 ± 0.87 l/nmol.
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The potential contribution of caspase-dependent apoptosis to survival under stress was assessed by addition of the pan-caspase inhibitor zVAD-FMK, which clearly increased starvation survival compared with control starved cells (Figure 4a) . However, the increased survival was independent of the IGFBP-3 expression status of the cells (Figure 4a ), suggesting that IGFBP-3 promotion of survival under stress is not dependent on the association of GRP78 with proapoptotic proteins.
In agreement with the pharmacological inhibition of autophagy, the IGFBP-3 survival advantage was lost upon knockdown of two essential autophagy components, Atg7 and Beclin I, verifying that an intact autophagic response is required (Figures 4b and c) . Furthermore, downregulation with two independent small interfering RNAs (siRNAs) indicated that GRP78 is required for IGFBP-3 promotion of survival. Importantly, IGFBP-3 expression was not influenced by knockdown of Atg7, Beclin-1 or GRP78 (Supplementary Figure 7) . Further evidence for a stress response role was provided by knockdown of endogenous IGFBP-3 in Hs578T breast cancer cells, where decreased survival after exposure to hypoxia and glucose starvation was observed (Figure 4d ).
Reports that high levels of autophagy are unfavorable for proliferation under nutrient-rich conditions 34 suggested that IGFBP-3 overstimulation of autophagy may inhibit growth under non-starvation conditions. However, we found that IGFBP-3 retained the ability to inhibit breast cancer cell growth under the standard culture conditions even when GRP78, Beclin I or Atg7 expression was knocked down (data not shown).
IGFBP-3 increases autophagic flux
We next determined whether IGFBP-3 promotes the initiation of autophagy and/or changes the rate of autophagic flux. First, we assessed a classical marker of autophagy, conversion of microtubule-associated protein 1 light chain 3-I (LC3-I) by attachment of phosphatidylethanolamine, which generates the faster-migrating LC3-II form incorporated into the inner and outer membranes of autophagosomes. 35 Under starvation conditions, IGFBP-3-expressing cells exhibited increased levels of LC3-II (Figure 5a ). Treatment of starved cells with the lysosomal inhibitors E64d and pepstatin A resulted in further accumulation of LC3-II in IGFBP-3-expressing cells, compared with non-IGFBP-3-expressing cells (Figures 5a and b) . This result indicated that the additional LC3-II was incorporated into functional autophagosomes, as degradation of the LC3-II molecules present in the inner membrane of autophagosomes, which occurs upon fusion with lysosomes, is inhibited by E64d and pepstatin A. 36 Next, a derivative of the clone 23 cell line that stably expressed a GFP-LC3 fusion protein was generated and used to assess the formation of autophagic puncta. Under starvation conditions, IGFBP-3 expression elevated the number of cells scoring positive for GFP-LC3 puncta (Supplementary Figure 8 and Figure 5c ). The increase in LC3 puncta positive cells caused by IGFBP-3 expression was abrogated by using 3-MA to inhibit autophagy (Figure 5c ).
Underglycosylation of IGFBP-3 promotes GRP78 binding and is induced by stress As hypoxia and glucose starvation both inhibit N-linked glycosylation, 37, 38 we assessed the effect of starvation on IGFBP-3 glycosylation and interaction with GRP78. GST pulldowns demonstrated a highly significant increase in GRP78 binding to an IGFBP-3 mutant in which all three glycosylation sites had been disrupted (Figure 6a) . Mutagenesis of the two invariant sites resulted in an intermediate, albeit not statistically significant, increase in binding. For the mutants that had a variable glycosylation pattern due to retention of the Asn 172 site, it would appear that in each case, the less glycosylated form of IGFBP-3 bound preferentially to GRP78 (Figure 6a) .
As expected, treatment of cells with tuni or 2-DG, which inhibit N-linked glycosylation, resulted in the production of IGFBP-3 that migrated with a molecular weight equivalent to that of the glycosylation-deficient mutant above (data not shown). Of more physiological relevance, starvation of IGFBP-3-expressing cells IGFBP-3 enhances autophagy and stress survival S Grkovic et al resulted in the appearance of underglycosylated IGFBP-3 in clone 23 cell lysates within 1 h, with almost complete loss of glycosylation by 4 h (Figure 6b ). Complete loss of glycosylation for endogenous IGFBP-3 was also observed after starvation of Hs578T cells (Figure 6c) . In both cases, the unglycosylated IGFBP-3 band migrated at a position equivalent to that of the triple N to A mutant in Figure 6a (data not shown) . These results suggest that underglycosylated IGFBP-3 produced as a consequence of stress exhibits increased GRP78 binding.
DISCUSSION
A TAP approach to gain insights into intracellular IGFBP-3-binding partners in breast cancer cells resulted in the identification of GRP78. The IGFBP-3-GRP78 interaction was subsequently verified by coimmunoprecipitations and GST pulldowns, which demonstrated that IGFBP-3 binding was mediated by lobe IIB of the GRP78 ATPase domain. Structural comparisons of human Hsp70 isoforms have revealed that a shift in the position of GRP78 lobe IIB is the only major difference between their ATPase domains. 23 Thus, additional evidence of a highly specific interaction is provided by IGFBP-3 binding to a portion of the GRP78 ATPase domain that may have unique functional as well as structural characteristics. Furthermore, of the five other IGFBPs, only IGFBP-5, which is the most closely related to IGFBP-3 with respect to structure and function, 1 was found to bind GRP78. Based on the lack of additional bands observed under the low-stringency TAP conditions, we propose that GRP78 could be one of the major intracellular binding partners of IGFBP-3 in breast cancer cells. The high degree of colocalization observed in breast cancer cell lines, combined with a binding affinity in the low nanomolar range, provides additional support for a physiological role for this interaction.
GRP78 promotion of breast cancer development, progression and therapeutic resistance 20, 21, 39, 40 has been linked to the UPR. 24 ,41 Therefore, we investigated the physiological significance of the IGFBP-3-GRP78 interaction in the context of stress conditions that are known to activate the UPR and mimic adverse in vivo microenvironments. Despite numerous reports that IGFBP-3 can act as an antiproliferative and proapoptotic molecule during the in vitro culture of breast cancer cells, 16, 17, 28, 42, 43 we instead observed a significant enhancement in the survival of IGFBP-3-expressing cells that had been subjected to hypoxia and glucose starvation.
A second unexpected finding was the inability of IGFBP-3 to perturb UPR signaling. Instead, pharmacological inhibitors and siRNA knockdown demonstrated that the IGFBP-3 promotion of survival was dependent on autophagy. Increases in both the rate of LC3 conversion and the number of LC3 puncta suggest that IGFBP-3 stimulates autophagic flux. 
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Our proposal that IGFBP-3 enhances autophagy via binding to GRP78 is consistent with a recent report that GRP78 is required for stress-induced autophagy. 18 The contribution of GRP78 to autophagy may be related to the ER being one of the probable sources of the autophagosomal double membrane in mammals. 44 Although ER expansion is dependent on XBP-1, we found that IGFBP-3 expression did not have any impact on splicing of XBP1 mRNA, which is significant in light of the suggestion that GRP78 may facilitate autophagy by preventing excessive XBP-1 activity.
18
A mechanistic understanding of how IGFBP-3 modifies GRP78 autophagy-related functions by binding to its ATPase domain awaits further elucidation of the relationship between GRP78 and autophagy. In the interim, confirmation that IGFBP-3 binding to GRP78 promotes autophagy and stress survival may be possible by the production of IGFBP-3 mutants, specifically deficient for this interaction. 
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The ability of IGFBP-3 to enhance the survival of cells challenged with microenvironmental stress represents a novel intracellular mechanism, whereby IGFBP-3 can promote the development of breast and other cancers. Almost all solid tumors at some stage need to adapt to adverse microenvironments that are characterized by hypoxia and nutrient starvation. This is particularly the case for breast carcinogenesis, as in the earliest stages, neoplastic cells are confined to the ducts (ductal carcinoma in situ), which, due to the absence of a blood supply, is a particularly hypoxic and nutrient-poor environment. 45 For this reason, autophagic recycling of cytoplasmic constituents to provide energy and essential nutrients has been proposed to be crucial for promoting the survival, adaptation and progression of pre-malignant neoplastic cells. 45 Thus, upregulation of IGFBP-3 may provide a distinct advantage in the early stages of breast carcinogenesis, consistent with observations that IGFBP-3 mRNA is elevated in benign tumors compared with adjacent normal tissue. 46 The impact of IGFBP-3 on more advanced tumors may be a function of their highly variable individual microenvironments.
The only previous report of a role for IGFBP-3 N-linked glycosylation was inhibition of cell-surface association. 47 We found that microenvironmental stress severely inhibited IGFBP-3 glycosylation and that an unglycosylated variant exhibited increased GRP78 binding. This points to a previously unrecognized biological role for IGFBP-3 glycosylation and provides further evidence that intracellular IGFBP-3 may have starvation-specific functions. Glycosylation of IGFBP-3 would provide an ideal mechanism to detect and immediately respond to starvation-induced stress, as N-linked glycosylation occurs in the ER, the same cellular compartment as that proposed for the IGFBP-3-GRP78 interaction. Occlusion of GRP78-interacting residues by the sugar chains on the IGFBP-3 surface provides a possible explanation for inhibition of binding. However, it is difficult to validate this proposal at present, because of our current lack of knowledge as to the IGFBP-3 amino acids involved in contacting GRP78, combined with the fact that the IGFBP-3 N-glycosylation attachment sites are located in a non-conserved region for which there is no structural information for any IGFBP.
That IGFBP-3 may specifically have a role under adverse conditions is also supported by reports that a substantial increase in IGFBP-3 expression occurs under hypoxia. 48, 49 Induction of IGFBP-3 expression by hypoxia, when combined with promotion of the GRP78 association via underglycosylation, may confer upon IGFBP-3 the ability to upregulate the recycling of nutrients and energy when it is most required. Such actions can clearly enhance tumor progression and could also aid tumor-cell survival when challenged by therapeutic agents.
An inability to convincingly link serum levels of IGFBP-3 to breast cancer outcomes, 2 combined with reports that high levels of IGFBP-3 protein in breast tumor tissue are indicative of a poor prognosis, [3] [4] [5] [6] 50 suggests that IGFBP-3 synthesized by tumor cells, rather than circulating IGFBP-3, may be important in facilitating breast cancer progression. Tumor-derived IGFBP-3 appears capable of promoting growth via a number of IGF-independent mechanisms, including the potentiation of epidermal growth factor receptor signaling via increased activation of sphingosine kinase, 51 as well as fibronectin-dependent stimulation of epidermal growth factor receptor internalization. 52 The enhancement of stress-induced autophagy represents another avenue, whereby IGFBP-3 can promote breast tumorigenesis. Further characterization of the links between IGFBP-3, GRP78, autophagy and breast cancer will help determine the relative importance of this newly discovered IGFBP-3 function.
MATERIALS AND METHODS
Cell culture
Unless stated, all cell culture products were from Thermo Fisher Scientific (Waltham, MA, USA). Breast cancer cell lines T47D, Hs578T, MDA-MB-468 (ATCC, Manassas, VA, USA) and MCF7 Tet-On Advanced (Clontech, Mountain View, CA, USA) were cultured in RPMI and HEK293 cells (ATCC) in DMEM, in each case supplemented with 10% fetal calf serum (SigmaAldrich, St Louis, MO, USA) and 10 mM Hepes. The standard culture conditions were 37 1C, 21% O 2 and 5% CO 2 in a humidified chamber, whereas starvation conditions utilized 1% O 2 and glucose-free RPMI (Sigma-Aldrich) supplemented with 3.5% dialyzed fetal calf serum. 53 The additives hygromycin and geneticin (Invitrogen, Carlsbad, CA, USA), puromycin, dox, tuni, 2-DG, 3-MA, wortmannin, E64d, pepstatin A (Sigma-Aldrich) and zVAD-FMK (Merck, Darmstadt, Germany) were used as required.
Plasmids, siRNA and transfections IGFBP-3 was cloned into pTRE-tight (Clontech) for dox-regulated expression and into a neomycin-resistant derivative of pCI (Promega, Madison, WI, USA) for TAP. GRP78 was also inserted into pCI-neo for mammalian expression. pGEX4T-1 (GE Healthcare Lifesciences, Buckinghamshire, UK) derivatives were used to produce GST-GRP78 fusion constructs. Cloning details are available on request. Wild-type and IGFBP-3 glycosylation constructs, 47 as well as pBABEpuro GFP-LC3 (Addgene no. 22405; Cambridge, MA, USA) 54 (provided by Jayanta Debnath, National Institute of Genetics, Mishima, Japan), have been previously described. Plasmids were transfected with Fugene HD (Roche, Basel, Switzerland). Ambion silencer-select siRNAs targeting BECN1 (s16537), ATG7 (s20650), GRP78 (s6980 and s6981) and NegCont no 1 were obtained from Invitrogen and custom IGFBP-3 siRNAs were from Qiagen (Valencia, CA, USA). A total of 20 nM of the IGFBP-3 and 5 nM of the silencer-select siRNAs were transfected as previously described. 43 Cell proliferation and colony forming assays
The standard cell counting assays were performed as previously described. 43 For starvation, cells were incubated under the standard conditions for 24 h (with the addition of dox for the final 12 h as required) prior to a phosphate-buffered saline wash and transfer to starvation conditions. Long-term colony forming assays were performed by starving cells as above for 16 h, prior to gentle trypsinization and the plating of dilutions on six-well dishes. After 3 weeks of growth under the standard conditions, dishes were stained with 0.5% crystal violet (Sigma-Aldrich) in 25% methanol for 5 min, rinsed twice with water, air-dried and colonies with 450 cells were counted. Each assay was performed in triplicate, with results expressed as means ± s.e.m.
TAP
Subconfluent cells grown on 500-cm 2 dishes were harvested by trypsinization, washed in phosphate-buffered saline and 6 g cells were resuspended in 0.34 M sucrose buffer before lysis of the plasma membrane by addition of 0.1% Triton X-100 to produce a crude nuclear/secretory pathway fraction, essentially as described. 55 The pelleted material was then suspended in buffer A (350 mM NaCl, 0.1% Triton X-100, 40 mM Tris-HCl pH 7.5, 1 mM EDTA and 5% glycerol) and incubated overnight with ANTI-FLAG M2 Affinity Gel (Sigma-Aldrich). Extensive washing was done with buffer A, then with buffer B (200 mM NaCl, 0.1% Triton X-100, 40 mM Tris-HCl pH 7.5, 1 mM MgCl 2 and 5% glycerol) prior to elution with 3 Â FLAG Peptide (Sigma-Aldrich) in buffer B. Eluted complexes were next incubated with NTA agarose (Qiagen) in buffer B supplemented with 5 mM imidazole for 4 h, before extensive washing with buffer B containing 15 mM imidazole. Proteins were eluted by boiling in SDS sample buffer lacking DTT and separated on a large format 8-16% gel. Buffers were supplemented with protease and phosphatase inhibitors (Roche). Bands were detected using the Silver Quest silver staining kit (Invitrogen), excised, digested with trypsin and peptides identified by MALDI-TOF peptide mass fingerprinting at the Australian Proteome Analysis Facility (Macquarie University, NSW, Australia).
Western blots, coimmunoprecipitation, GST pulldowns and binding affinity Whole-cell lysates prepared by sonication in modified RIPA buffer (1% NP40, 0.25% sodium deoxycholate, 0.05% SDS, 150 mM NaCl, 50 mM TrisHCl pH 7.5 and 1 mM EDTA) were loaded at 10-20 mg per lane and subjected to western blot analysis as described. 43 Primary antibodies included GRP78 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), GRP94 (Abcam, Cambridge, UK), LC3 (Novus Biologicals, St Charles, MO, USA), IGFBP-3 enhances autophagy and stress survival S Grkovic et al FLAG (Stratagene, La Jolla, CA, USA), Atg7 and Beclin-1 (Cell Signaling Technology, Beverly, MA, USA), actin and tubulin (Sigma-Aldrich) and IGFBP-3. 43 Whole-cell lysates for coimmunoprecipitations were prepared by sonication in NP40 buffer (1% NP40, 150 mM NaCl and 40 mM Tris pH 7.5). Clarified lysates were then incubated for 3 h with primary antibodies, 1 h with protein G-agarose (Roche) and extensively washed with NP40 buffer. GST fusion proteins were expressed in Escherichia coli BL21 cells and purified on glutathione sepharose 4B agarose (GE Healthcare Lifesciences) as described previously. 56 IGF ligand blots 43 and GST pulldowns, 57 were performed as described. Buffers were supplemented with protease and phosphatase inhibitors. The binding affinity of 125 I-labeled IGFBP-3 for GST-GRP78 immobilized on glutathione sepharose 4B agarose was measured by competition with increasing concentrations of unlabeled IGFBP-3, essentially as described previously. 58 
Indirect immunofluorescence
Cells grown on glass coverslips were processed for indirect immunofluorescence as previously described, 59 mounted in ProLong Gold antifade reagent with DAPI (Invitrogen) and data collected on a Leica TCS SP5 laser scanning confocal microscope. For quantitation of GFP-LC3 puncta, cells were permeabilized by a 5-min treatment with 0.025% digitonin (Merck) immediately prior to fixation to remove soluble, non-membrane-bound LC3. 60 An Olympus BX60 microscope (North Ryde, NSW, Australia) with a Â 63 oil immersion objective and DP71 camera and software were used to capture images. Identical settings were used to acquire each set of images.
Statistical analysis
Unless stated otherwise, comparisons among groups were analyzed by factorial analysis of variance with post-hoc testing by Fisher's protected least significant test (Statview 5.0; Abacus Concepts Inc, Berkeley, CA, USA). A significant difference was defined as Po0.05.
